Cancer Research Meeting Calendar Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rohayem, J.
Right arrow Articles by Rieber, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rohayem, J.
Right arrow Articles by Rieber, E. P.
[Cancer Research 60, 1815-1817, April 1, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Antibody Response to the Tumor-associated Inhibitor of Apoptosis Protein Survivin in Cancer Patients1

Jacques Rohayem, Petra Diestelkoetter, Bernd Weigle, Antje Oehmichen, Marc Schmitz, Juergen Mehlhorn, Karsten Conrad and Ernst Peter Rieber2

Institute for Immunology, Medical Faculty, Technical University of Dresden, 01101 Dresden [J. R., P. D., B. W., A. O., M. S., K. C., E. P. R.], and Medical Opinion Community Niederdorf [J. M.], 09366 Niederdorf, Germany

Antibody reactivity against survivin, a recently identified tumor-associated protein, was determined in sera from patients with lung (n = 51) or colorectal cancer (n = 49). The same collection of sera was tested for the presence of antibodies against p53. Eleven sera from lung cancer patients and four sera from colorectal cancer patients reacted with purified recombinant survivin in an ELISA (21.6% and 8.2%, respectively), whereas four sera from lung cancer patients and nine sera from colorectal cancer patients contained anti-p53 antibodies (7.8% and 18.4%, respectively). The increase in prevalence when anti-survivin and anti-p53 antibodies were determined in parallel was statistically significant (29.4% versus 7.8%, P = 0.005 in lung cancer population; 26.6% versus 8.2%, P = 0.015 in colorectal cancer population). The high prevalence of anti-survivin antibodies makes these antibodies an attractive novel marker for the diagnosis of lung and colorectal cancer, particularly in patients lacking anti-p53 antibodies.




This article has been cited by other articles:


Home page
 Acta Biochim Biophys SinHome page
J. Shen, J. Liu, Y. Long, Y. Miao, M. Su, Q. Zhang, H. Han, and X. Hao
Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity
Acta Biochim Biophys Sin, March 1, 2009; 41(3): 223 - 230.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Schaue, B. Comin-Anduix, A. Ribas, L. Zhang, L. Goodglick, J. W. Sayre, A. Debucquoy, K. Haustermans, and W. H. McBride
T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy
Clin. Cancer Res., August 1, 2008; 14(15): 4883 - 4890.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X.-F. Wang, J. Kerzerho, O. Adotevi, H. Nuyttens, C. Badoual, G. Munier, S. Oudard, S. Tu, E. Tartour, and B. Maillere
Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients
J. Immunol., July 1, 2008; 181(1): 431 - 439.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Pennati, M. Folini, and N. Zaffaroni
Targeting survivin in cancer therapy: fulfilled promises and open questions
Carcinogenesis, June 1, 2007; 28(6): 1133 - 1139.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Grube, S. Moritz, E. C. Obermann, K. Rezvani, A. Mackensen, R. Andreesen, and E. Holler
CD8+ T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma
Clin. Cancer Res., February 1, 2007; 13(3): 1053 - 1060.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
J. Rohayem, K. Jager, I. Robel, U. Scheffler, A. Temme, and W. Rudolph
Characterization of norovirus 3Dpol RNA-dependent RNA polymerase activity and initiation of RNA synthesis
J. Gen. Virol., September 1, 2006; 87(9): 2621 - 2630.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. C. Altieri
Targeted therapy by disabling crossroad signaling networks: the survivin paradigm.
Mol. Cancer Ther., March 1, 2006; 5(3): 478 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ho, R. Hassan, J. Zhang, Q.-c. Wang, M. Onda, T. Bera, and I. Pastan
Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients
Clin. Cancer Res., May 15, 2005; 11(10): 3814 - 3820.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Iwata, T. Fujita, N. Hirao, Y. Matsuzaki, T. Okada, H. Mochimaru, N. Susumu, E. Matsumoto, K. Sugano, N. Yamashita, et al.
Frequent Immune Responses to a Cancer/Testis Antigen, CAGE, in Patients with Microsatellite instability-Positive Endometrial Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3949 - 3957.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
M. E. Johnson and E. W. Howerth
Survivin: A Bifunctional Inhibitor of Apoptosis Protein
Vet. Pathol., November 1, 2004; 41(6): 599 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Lu, Y. Mu, C. Cao, F. Zeng, S. Schneider, J. Tan, J. Price, J. Chen, M. Freeman, and D. E. Hallahan
Survivin As a Therapeutic Target for Radiation Sensitization in Lung Cancer
Cancer Res., April 15, 2004; 64(8): 2840 - 2845.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Pisarev, B. Yu, R. Salup, S. Sherman, D. C. Altieri, and D. I. Gabrilovich
Full-Length Dominant-Negative Survivin for Cancer Immunotherapy
Clin. Cancer Res., December 15, 2003; 9(17): 6523 - 6533.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Koziol, J.-Y. Zhang, C. A. Casiano, X.-X. Peng, F.-D. Shi, A. C. Feng, E. K. L. Chan, and E. M. Tan
Recursive Partitioning as an Approach to Selection of Immune Markers for Tumor Diagnosis
Clin. Cancer Res., November 1, 2003; 9(14): 5120 - 5126.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Casati, P. Dalerba, L. Rivoltini, G. Gallino, P. Deho, F. Rini, F. Belli, D. Mezzanzanica, A. Costa, S. Andreola, et al.
The Apoptosis Inhibitor Protein Survivin Induces Tumor-specific CD8+ and CD4+ T Cells in Colorectal Cancer Patients
Cancer Res., August 1, 2003; 63(15): 4507 - 4515.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Yagihashi, K. Asanuma, N. Tsuji, T. Torigoe, N. Sato, K. Hirata, and N. Watanabe
Detection of Anti-Livin Antibody in Gastrointestinal Cancer Patients
Clin. Chem., July 1, 2003; 49(7): 1206 - 1208.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J.-Y. Zhang, C. A. Casiano, X.-X. Peng, J. A. Koziol, E. K. L. Chan, and E. M. Tan
Enhancement of Antibody Detection in Cancer Using Panel of Recombinant Tumor-associated Antigens
Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 136 - 143.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Hirohashi, T. Torigoe, A. Maeda, Y. Nabeta, K. Kamiguchi, T. Sato, J. Yoda, H. Ikeda, K. Hirata, N. Yamanaka, et al.
An HLA-A24-restricted Cytotoxic T Lymphocyte Epitope of a Tumor-associated Protein, Survivin
Clin. Cancer Res., June 1, 2002; 8(6): 1731 - 1739.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Yagihashi, K. Asanuma, M. Nakamura, J. Araya, Y. Mano, T. Torigoe, D. Kobayashi, and N. Watanabe
Detection of Anti-Survivin Antibody in Gastrointestinal Cancer Patients
Clin. Chem., September 1, 2001; 47(9): 1729 - 1731.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
M. H. Andersen, L. O. Pedersen, B. Capeller, E.-B. Brocker, J. C. Becker, and P. thor Straten
Spontaneous Cytotoxic T-Cell Responses against Survivin-derived MHC Class I-restricted T-Cell Epitopes in Situ As Well As ex Vivo in Cancer Patients
Cancer Res., August 1, 2001; 61(16): 5964 - 5968.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. H. Andersen, L. O. Pedersen, J. C. Becker, and P. t. Straten
Identification of a Cytotoxic T Lymphocyte Response to the Apoptosis Inhibitor Protein Survivin in Cancer Patients
Cancer Res., February 1, 2000; 61(3): 869 - 872.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.